Clearpoint Neuro, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Clearpoint Neuro, Inc. on September 20, 2022. The filing discloses the appointment of Mazin Sabra as Chief Operating Officer (COO), effective October 10, 2022. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol CLPT.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment terms.
Material Changes and Executive Appointment
The primary material change is the appointment of Mazin Sabra as COO. Mr. Sabra brings significant experience from Philips (Vice President of Supplier Quality Engineering) and Stryker Corporation (11 years in various management roles, including Director of Asia Strategic Sourcing). His background includes supply risk management, procurement strategy, and global supplier oversight for medical devices.
Compensatory Arrangements and Terms
- Base Salary: $340,000 annually, subject to adjustment by the Compensation Committee.
- Annual Incentive Bonus: Target of 45% of base salary, contingent on performance goals.
- Signing Bonus: $110,000 total ($50,000 within 45 days of start; $60,000 by March 31, 2023).
- Equity Grant: 46,000 restricted shares of common stock, vesting in three equal tranches over three years.
- Term: Three-year initial term with automatic one-year renewals.
- Termination Provisions:
- Without Cause/Good Reason: One year of base salary, average bonus of prior two years, $18,000, and full acceleration of unvested equity.
- Change of Control: Full acceleration of equity. If terminated within 12 months of a change of control, the payout increases to two times base salary and two times the average bonus of the prior three years.
Risks and Contingencies
The filing notes standard restrictive covenants including non-competition and non-solicitation agreements for one year post-employment. The company will also enter into a standard indemnification agreement covering legal expenses and judgments arising from Mr. Sabra's service as an officer.
Investor Verification Checklist
- Verify the impact of the new COO's supply chain expertise on the company's manufacturing and product development timelines.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific performance metrics tied to the annual bonus.
- Monitor the vesting schedule of the 46,000 restricted shares and potential dilution effects.
- Assess the financial implications of the $110,000 signing bonus and potential severance liabilities in the context of the company's current cash position (data not provided in this filing).